spot_img

      Subscribe Now!

 

Tuesday, May 24, 2022
spot_img
spot_img

Bryn Mawr Hospital is the First Hospital in the State to Implant Newly Approved WATCHMAN(tm) LAAC Device

Hellenic News
Hellenic News
The copyrights for these articles are owned by HNA. They may not be redistributed without the permission of the owner. The opinions expressed by our authors do not necessarily reflect the opinions of HNA and its representatives.

Latest articles

New technology can dramatically improve the care model for patients at risk for stroke

(Bryn Mawr, PA, August 19, 2015) – Bryn Mawr Hospital, part of Main Line Health’s Lankenau Heart Institute, is the first hospital in Pennsylvania to offer patients with non-valvular atrial fibrillation (AF) an alternative to long-term warfarin medication with the newly approved WATCHMAN™ Left Atrial Appendage Closure (LAAC) Implant, from developer Boston Scientific.

 

“This tool provides physicians with a breakthrough stroke risk reduction option for appropriate patients,” said Sheetal Chandhok, MD, Bryn Mawr Hospital cardiologist, part of the Lankenau Heart Institute, who performed the first percutaneous implant of the WATCHMAN device in Pennsylvania. “The WATCHMAN device offers a potentially life-changing stroke risk treatment option which could free patients from the challenges of long-term warfarin therapy.”

 

The WATCHMAN device is indicated for patients who have an appropriate rationale from their physician to seek a non-medical alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.”

Thanks for reading Hellenic News of America

 

The WATCHMAN LAAC Implant closes off an area of the heart called the left atrial appendage (LAA) to keep harmful blood clots from entering the blood stream and potentially causing a stroke. By closing off the LAA, the risk of stroke may be reduced and, over time, patients may be able to stop taking warfarin.
“The addition of the Watchman device further expands the treatment options we can offer to our patients with structural heart disease,” adds Steven Rothman, MD, Campus Chief, Cardiovascular Disease, Lankenau Medical Center. “With the expertise offered by our physicians at Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital, the Lankenau Heart Institute team continues to provide our patients with innovative solutions for their heart health needs.”

AF is a heart condition where the upper chambers of the heart beat too fast and with irregular rhythm. People with AF have a five times greater risk of stroke. It can cause blood to pool and form clots in the LAA. For patients with non-valvular AF, the LAA is believed to be the source of the majority of stroke-causing blood clots, and if a clot forms in the LAA, it can increase one’s risk of having a stroke. Blood clots can also break loose and travel in the blood stream to the brain, lungs, and other parts of the body.

 

The WATCHMAN device is indicated for patients who have an appropriate rationale from their physician to seek a non-medical alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. Implanting the WATCHMAN Device is a one-time procedure that usually lasts about an hour. Following the procedure, patients typically need to stay in the hospital for 24 hours. The WATCHMAN Implant has been approved in Europe since 2005 and is FDA-approved in the United States. It has been implanted in more than 10,000 patients and is approved in more than 70 countries around the world.

 

For more information on the WATCHMAN Implant, please visit: watchmanimplant.com

 

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit:  www.bostonscientific.com.

 

About the Lankenau Heart Institute

The Lankenau Heart Institute is Main Line Health System’s premier, comprehensive cardiovascular medicine and surgery program. The Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care Hospitals and 15 community cardiology practices to ensure that patients receive a level of quality, service, and experience that is unprecedented in the region. Through the System-wide coordination of services, the Lankenau Heart Institute delivers preventive, diagnostic, therapeutic, and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.

 

With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained nurses and technologists, the Lankenau Heart Institute is dedicated to managing and treating patients with heart failure, aortic disease, coronary and peripheral vascular disease, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac specialists provide patients and their families with expert cardiac care, close to home.

 Sources:

  1. Holmes DR, Seminars in Neurology 2010; 30:528–536
  2. Blackshear J. and Odell J., Annals of Thoracic Surgery. 1996;61:755-759
  3. Colilla et al., Am J Cardiol. 2013; 112:1142-1147
  4. Hart RG, Halperin JL., Ann Intern Med. 1999; 131:688–695
  5. McGrath ER, Neurology 2013; 81:825-832
  6. Waldo, AL. JACC 2005; 46:1729-1736

The copyrights for these articles are owned by the Hellenic News of America. They may not be redistributed without the permission of the owner. The opinions expressed by our authors do not necessarily reflect the opinions of the Hellenic News of America and its representatives.

Get Access Now!

spot_img
spot_img
spot_img